Safety, tolerability and efficacy of the use of <scp>tixagevimab/cilgavimab</scp> as pre‐exposure <scp>COVID‐19</scp> prophylaxis in kidney and simultaneous pancreas kidney transplant recipients
The COVID-19 pandemic resulted in high mortality rates in immunocompromised people, especially those who have received solid organ transplants. In this cohort of 540 transplant recipients who received tixagevimab/cilgavimab (Evusheld®) in Australia and New Zealand between January 2022 and January 2023, 11 (2%) Evusheld®-treated recipients experienced moderate to severe COVID-19 infection, with two deaths from COVID-19 pneumonitis. Less than 0.5% experienced adverse events from Evusheld®. Prophylactic monoclonal antibody therapy may be considered an important adjunct to vaccination among immunocompromised patients to prevent severe infection during future viral outbreaks.
Authors
- Stella McGinn (ORCID: https://orcid.org/0000-0002-1345-7443)
- Armando Teixeira‐Pinto (ORCID: https://orcid.org/0000-0002-9389-2516)
- Anh Kieu
- Germaine Wong (ORCID: https://orcid.org/0000-0001-8422-7269)
- Wai H. Lim (ORCID: https://orcid.org/0000-0002-3410-3572)
- Helen Pilmore (ORCID: https://orcid.org/0000-0003-1069-9487)
- Anoushka Krishnan
- Owen Ng (ORCID: https://orcid.org/0009-0005-9414-675X)
- Jian Wang (ORCID: https://orcid.org/0009-0008-2115-6078)
Institutions
- Edith Cowan University (AU)
- The University of Sydney (AU)
- University of Auckland (NZ)
- The University of Western Australia (AU)
- Royal Perth Hospital (AU)
- Royal North Shore Hospital (AU)
- Auckland City Hospital (NZ)
- Sir Charles Gairdner Hospital (AU)
- Children's Hospital at Westmead (AU)
- Westmead Hospital (AU)
- Sydney Local Health District (AU)
Publication Details
- Journal
- Internal Medicine Journal
- Published
- 2025-09-27
- DOI
- https://doi.org/10.1111/imj.70179
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00